UBS Group’s Neurocrine Biosciences NBIX Stock Holding History

UBS Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,400	Closed	-$1.56M	–	10721
2025 Q2	$1.56M	Buy	+12,400	New	+$1.42M	﹤0.01%	5057
2020 Q2	–	Sell	-40,000	Closed	-$3.46M	–	8208
2020 Q1	$3.46M	Buy	+40,000	New	+$3.91M	﹤0.01%	2253
2019 Q3	–	Sell	-27,400	Closed	-$2.31M	–	8156
2019 Q2	$2.31M	Sell	27,400 -700	-2%	-$57.5K	﹤0.01%	3021
2019 Q1	$2.48M	Buy	+28,100	New	+$2.35M	﹤0.01%	2813
2016 Q1	–	Sell	-100	Closed	-$6K	–	7976
2015 Q4	$6K	Hold	100	–	–	﹤0.01%	7614
2015 Q3	$4K	Sell	100 -123,800	-100%	-$5.98M	﹤0.01%	7829
2015 Q2	$5.92M	Buy	123,900 +41,300	+50%	+$1.75M	﹤0.01%	1899
2015 Q1	$3.28M	Sell	82,600 -157,600	-66%	-$5.64M	﹤0.01%	2456
2014 Q4	$5.37M	Buy	+240,200	New	+$4.55M	﹤0.01%	2031

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's NBIX Position: Q1 2026 in Review

UBS Group increased its Neurocrine Biosciences (NBIX) stake by 24% in Q1 2026, buying an estimated $31.5M and bringing the position to 1,221,036 shares worth $161M. The position accounts for 0.02% of the portfolio, ranked #726.

UBS Group first reported a position in NBIX in Q4 2014 and has held it in 46 quarters since. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

UBS Group held 1,221,036 shares of Neurocrine Biosciences worth $161M as of Q1 2026.
UBS Group bought 237,508 Neurocrine Biosciences shares in Q1 2026, an estimated $31.5M.
Neurocrine Biosciences made up 0.02% of UBS Group's portfolio in Q1 2026, its #726 holding.
UBS Group first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 46 quarters since.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.